Keyword Connections

•  Thomas Andl

Resources

• No matching connections

Communities

• No matching connections

Publications

• RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
  Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R
  (2012) N Engl J Med 366: 207-15
• Improved survival with ipilimumab in patients with metastatic melanoma.
  Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ
  (2010) N Engl J Med 363: 711-23
• Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling.
  Yang SH, Andl T, Grachtchouk V, Wang A, Liu J, Syu LJ, Ferris J, Wang TS, Glick AB, Millar SE, Dlugosz AA
  (2008) Nat Genet 40: 1130-5
• Perp is a p63-regulated gene essential for epithelial integrity.
  Ihrie RA, Marques MR, Nguyen BT, Horner JS, Papazoglu C, Bronson RT, Mills AA, Attardi LD
  (2005) Cell 120: 843-56
• Genomic Classification of Cutaneous Melanoma.
  Cancer Genome Atlas Network
  (2015) Cell 161: 1681-96
• p120-catenin mediates inflammatory responses in the skin.
  Perez-Moreno M, Davis MA, Wong E, Pasolli HA, Reynolds AB, Fuchs E
  (2006) Cell 124: 631-44
• Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype.
  Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC
  (1995) Science 269: 230-4
• Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.
  Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V
  (1997) Science 277: 225-8
• Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
  Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS
  (2012) Lancet Oncol 13: 459-65
• Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis.
  Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T, Cronberg T, Isshiki A, Erickson HP, Fässler R
  (2001) Nat Med 7: 324-30
• A dermal niche for multipotent adult skin-derived precursor cells.
  Fernandes KJ, McKenzie IA, Mill P, Smith KM, Akhavan M, Barnabé-Heider F, Biernaskie J, Junek A, Kobayashi NR, Toma JG, Kaplan DR, Labosky PA, Rafuse V, Hui CC, Miller FD
  (2004) Nat Cell Biol 6: 1082-93
• Treating Flu with Skin of Frog.
  Crowe JE
  (2017) Immunity 46: 517-518
• Complications of acute leukemia. Case one: congenital acute myelogenous leukemia with cutaneous involvement.
  Frangoul HA, Patterson K
  (1998) J Clin Oncol 16: 3199-200
• Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort.
  Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M, Hammond S, Yasui Y, Inskip PD
  (2009) J Clin Oncol 27: 2356-62
• Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.
  Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA, Kudchadkar RR, Sosman JA
  (2015) J Clin Oncol 33: e122-4
• Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation.
  Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ
  (2006) J Clin Oncol 24: 1119-26
• Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
  Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A
  (2013) J Clin Oncol 31: 1767-74
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
  Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS
  (2014) J Clin Oncol 32: 1020-30
• Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
  Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP
  (2013) J Clin Oncol 31: 4387-93
• BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
  Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ
  (2012) J Clin Oncol 30: 34-41
• Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
  Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD
  (2013) J Clin Oncol 31: 482-9
• Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
  Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK, Southwest Oncology Group
  (2002) J Clin Oncol 20: 2067-75
• When will melanoma vaccines be proven effective?
  Sosman JA, Weeraratna AT, Sondak VK
  (2004) J Clin Oncol 22: 387-9
• Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
  Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW, Fletcher WS, Weiss GR, Unger JM, Sondak VK
  (1998) J Clin Oncol 16: 664-9
• Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.
  McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT, Callahan J, Hicks RJ
  (2012) J Clin Oncol 30: 1628-34
• The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
  Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB
  (2013) Nat Rev Clin Oncol 10: 588-98
• High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing.
  Hodges E, Smith AD, Kendall J, Xuan Z, Ravi K, Rooks M, Zhang MQ, Ye K, Bhattacharjee A, Brizuela L, McCombie WR, Wigler M, Hannon GJ, Hicks JB
  (2009) Genome Res 19: 1593-605
• Sunlight and reduced risk of cancer: is the real story vitamin D?
  Egan KM, Sosman JA, Blot WJ
  (2005) J Natl Cancer Inst 97: 161-3
• Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
  Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A
  (2016) J Natl Cancer Inst 108: djv406
• Immune cell populations in cutaneous delayed-type hypersensitivity.
  Platt JL, Grant BW, Eddy AA, Michael AF
  (1983) J Exp Med 158: 1227-42
• CD4+ but not CD8+ cells are essential for allorejection.
  Krieger NR, Yin DP, Fathman CG
  (1996) J Exp Med 184: 2013-8
• Bee venom stirs up buzz in antigen presentation.
  Van Kaer L
  (2015) J Exp Med 212: 126
• WNT signals are required for the initiation of hair follicle development.
  Andl T, Reddy ST, Gaddapara T, Millar SE
  (2002) Dev Cell 2: 643-53
• Blocked acinar development, E-cadherin reduction, and intraepithelial neoplasia upon ablation of p120-catenin in the mouse salivary gland.
  Davis MA, Reynolds AB
  (2006) Dev Cell 10: 21-31
• Reciprocal requirements for EDA/EDAR/NF-kappaB and Wnt/beta-catenin signaling pathways in hair follicle induction.
  Zhang Y, Tomann P, Andl T, Gallant NM, Huelsken J, Jerchow B, Birchmeier W, Paus R, Piccolo S, Mikkola ML, Morrisey EE, Overbeek PA, Scheidereit C, Millar SE, Schmidt-Ullrich R
  (2009) Dev Cell 17: 49-61
• Collagen-mediated platelet aggregation. Evidence for multivalent interactions of intermediate specificity between collagen and platelets.
  Santoro SA, Cunningham LW
  (1977) J Clin Invest 60: 1054-60
• Epithelial stem cell mutations that promote squamous cell carcinoma metastasis.
  White RA, Neiman JM, Reddi A, Han G, Birlea S, Mitra D, Dionne L, Fernandez P, Murao K, Bian L, Keysar SB, Goldstein NB, Song N, Bornstein S, Han Z, Lu X, Wisell J, Li F, Song J, Lu SL, Jimeno A, Roop DR, Wang XJ
  (2013) J Clin Invest 123: 4390-404